BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 20, 2020
View Archived Issues
Engineering better bacterial backstabbers
Read More
Targeting bystander protein improves sepsis outcome
Read More
Phase II study of Ad5-nCoV vaccine in healthy adults
Read More
Revive partners with Complete Phytochemical Solutions to develop psilocybin-based products
Read More
New spiroindoline derivatives show potential as remyelinating agents
Read More
PS-PLA1 as new therapeutic target in hyperthyroidism disorders
Read More
Chinese researchers patent RET inhibitors
Read More
Medshine Discovery presents new TRK inhibitors
Read More
Beijing Heli Consulting identifies polypeptide conjugates of odanacatib
Read More
Nanjing Gentai Pharmaceutical Technology identifies BTK inhibitors
Read More
Cancer drug delivery system targets tumor extracellular matrix, avoids healthy tissue
Read More
Roche describes new TLR antagonists
Read More
Ribonucleoside analogue EIDD-1931 is potently active against coronaviruses
Read More
New genetic variants in SLC34A2 gene tied to lung microlithiasis
Read More
Pemazyre approved in U.S. for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements
Read More
FDA clears anti-Claudin 18.2 antibody TST-001 to enter clinical trials for metastatic solid tumors
Read More
FDA approves Tukysa for advanced, unresectable or metastatic HER2-positive breast cancer
Read More
Initiation of phase III RUXCOVID trial of ruxolitinib for COVID-19-associated cytokine storm
Read More
Novartis plans phase III study of hydroxychloroquine in hospitalized patients with COVID-19 disease
Read More
Idorsia reports first pivotal results with daridorexant in insomnia
Read More
U.K. MHRA clears 4D Pharma to begin phase II study of MRx-4DP0004 in COVID-19
Read More
Ascendis reports fixed-dose TransCon PTH data from phase II PaTH Forward trial in hypoparathyroidism
Read More
Kazia updates findings from phase I study of Cantrixil in ovarian cancer
Read More